Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard E Chaisson

Showing results (191-200 of 241) with videos related to

Pageof 25
Sort By:
AIDS (London, England)|October 1, 2019
Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIVEmily A Kendall, Betina Durovni, Neil A Martinson, et al.
Antiviral Therapy|June 12, 2013
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South AfricaChristopher J Hoffmann, Johanna Ledwaba, Jin-Fen Li, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2024
Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With HIV in the North West Province of South Africa (the Teko Study): A Cluster Randomized TrialBrooke A Jarrett, Kate Shearer, Katlego Motlhaoleng, et al.
Lancet (London, England)|April 7, 2009
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialMarcus B Conde, Anne Efron, Carla Loredo, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2022
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based DosingMichelle M Pham, Anthony T Podany, Noluthando Mwelase, et al.
American Journal of Epidemiology|October 14, 2008
Validation of a hierarchical deterministic record-linkage algorithm using data from 2 different cohorts of human immunodeficiency virus-infected persons and mortality databases in BrazilAntonio G Pacheco, Valeria Saraceni, Suely H Tuboi, et al.
BMC Public Health|March 1, 2006
Predicting smear negative pulmonary tuberculosis with classification trees and logistic regression: a cross-sectional studyFernanda Carvalho de Queiroz Mello, Luiz Gustavo do Valle Bastos, Sérgio Luiz Machado Soares, et al.
AIDS (London, England)|June 1, 2016
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected personsTimothy R Sterling, Nigel A Scott, Jose M Miro, et al.
Plos Medicine|February 10, 2026
Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trialBetina Durovni, Marcelo Cordeiro-Santos, Solange Cesar Cavalcante, et al.
The Lancet. HIV|April 3, 2020
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trialKelly E Dooley, Radojkam Savic, Akshay Gupte, et al.
Pageof 25

Showing results (191-200 of 241) with videos related to

Sort By:
Pageof 25
AIDS (London, England)|October 1, 2019
Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIVEmily A Kendall, Betina Durovni, Neil A Martinson, et al.
Antiviral Therapy|June 12, 2013
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South AfricaChristopher J Hoffmann, Johanna Ledwaba, Jin-Fen Li, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2024
Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With HIV in the North West Province of South Africa (the Teko Study): A Cluster Randomized TrialBrooke A Jarrett, Kate Shearer, Katlego Motlhaoleng, et al.
Lancet (London, England)|April 7, 2009
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialMarcus B Conde, Anne Efron, Carla Loredo, et al.
Antimicrobial Agents and Chemotherapy|August 9, 2022
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based DosingMichelle M Pham, Anthony T Podany, Noluthando Mwelase, et al.
American Journal of Epidemiology|October 14, 2008
Validation of a hierarchical deterministic record-linkage algorithm using data from 2 different cohorts of human immunodeficiency virus-infected persons and mortality databases in BrazilAntonio G Pacheco, Valeria Saraceni, Suely H Tuboi, et al.
BMC Public Health|March 1, 2006
Predicting smear negative pulmonary tuberculosis with classification trees and logistic regression: a cross-sectional studyFernanda Carvalho de Queiroz Mello, Luiz Gustavo do Valle Bastos, Sérgio Luiz Machado Soares, et al.
AIDS (London, England)|June 1, 2016
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected personsTimothy R Sterling, Nigel A Scott, Jose M Miro, et al.
Plos Medicine|February 10, 2026
Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trialBetina Durovni, Marcelo Cordeiro-Santos, Solange Cesar Cavalcante, et al.
The Lancet. HIV|April 3, 2020
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trialKelly E Dooley, Radojkam Savic, Akshay Gupte, et al.
Pageof 25